Aquaretic Agents: Whats Beyond the Treatment of Hyponatremia?

Author(s): Davide Bolignano, Giuseppe Coppolino, Manila Criseo, Susanna Campo, Adolfo Romeo, Michele Buemi.

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 8 , 2007

Become EABM
Become Reviewer

Abstract:

Unlike the more commonly used diuretics, aquaretic agents can induce an increase in urinary volume without incurring a loss of electrolytes. These molecules belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate optional renal water re-absorption via the synthesis and expression of aquaporin-2. In view of their properties, they have become the agent of choice in the treatment of hyponatremic states with water retention, and different studies have demonstrated that they are more effective and practical to use than other traditional approaches in the treatment of diseases such as cirrhosis-related ascites, SIADH and, above all, heart failure. However, the future probably holds the promise of new and unexpected applications for this type of drug in the treatment of several conditions, including polycystic kidney and glomerular disease, glaucoma and Menieres syndrome.

Keywords: Aquaretic, hyponatremia, heart failure, vasopressin, V2 antagonists

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 8
Year: 2007
Page: [865 - 871]
Pages: 7
DOI: 10.2174/138161207780363040
Price: $58

Article Metrics

PDF: 1